{
  "id": "5c6b82a17c78d6947100002f",
  "type": "yesno",
  "question": "Is verubecestat effective for Alzheimer\u2019s Disease?",
  "ideal_answer": "No. Verubecestat is not effective for treatment of Alzheimer\u2019s Disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29461065",
    "http://www.ncbi.nlm.nih.gov/pubmed/28749667",
    "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
    "http://www.ncbi.nlm.nih.gov/pubmed/29397980"
  ],
  "snippets": [
    {
      "text": " The lack of efficacy of verubecestat in mild-to-moderate AD raises important questions about the timing of intervention with BACE-1 inhibitors, and anti-amyloid therapies in general, in AD treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28749667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29461065",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Verubecestat is an inhibitor of \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) being evaluated in clinical trials for the treatment of Alzheimer's disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29397980",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS\nVerubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29719179",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}